SLC5A2 and type 2 diabetes mellitus: SGLT2 inhibition raises circulation levels and zinc 2 glycoprotein gene expression (encoded by the AZGP1 gene) in T2DM patients (Figure 3), improving insulin sensitivity [79] (Table 2).